home / stock / clbtw / clbtw news


CLBTW News and Press, Cellebrite DI Ltd. Warrants

Stock Information

Company Name: Cellebrite DI Ltd. Warrants
Stock Symbol: CLBTW
Market: NASDAQ
Website: cellebrite.com

Menu

CLBTW CLBTW Quote CLBTW Short CLBTW News CLBTW Articles CLBTW Message Board
Get CLBTW Alerts

News, Short Squeeze, Breakout and More Instantly...

CLBTW - Small-Cap Stocks 2024 Second Half Outlook - Buy Small Caps

2024-07-16 07:00:00 ET Summary Small-cap stocks struggled in the first half of 2024 due to economic concerns and higher interest rates, lagging behind broader market indexes. The outlook for small caps in the second half depends on timely interest rate cuts and stable economic gro...

CLBTW - Cellebrite to Report Second-Quarter 2024 Financial Results on August 15, 2024

TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 09, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its second-quarter 2024 financial results before market open o...

CLBTW - Cellebrite Announces Availability of Industry-Leading Endpoint Inspector SaaS Solution on Amazon Web Services Marketplace

TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today that its Endpoint Inspector SaaS, the Company’s real-time data access, col...

CLBTW - Cellebrite DI Ltd. (CLBT) Q1 2024 Earnings Call Transcript

2024-05-23 15:09:07 ET Cellebrite DI Ltd. (CLBT) Q1 2024 Earnings Call Transcript May 23, 2024, 08:30 AM ET Company Participants Andrew Kramer - IR Yossi Carmil - CEO Dana Gerner - CFO Conference Call Participants Shaul Eyal - TD Cowen Jonathan Ho...

CLBTW - Cellebrite Announces First-Quarter 2024 Results

ARR of $331.8 million, up 27% year-over-year; Q1 2024 revenue of $89.6 million, up 26% year-over-year primarily due to 29% growth in subscription revenue; Q1 2024 adjusted EBITDA of $17.6 million, 19.7% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, M...

CLBTW - Greenhaven Road Capital - Cellebrite: Own A Growing, Cash Flowing, Below Market Multiple Company

2024-05-01 08:05:00 ET Summary Cellebrite is another technology company, making its results also not inevitable, but I do like their prospects. Despite this mission-critical offering, Cellebrite typically represents less than 1/10 of 1% of their customers’ budgets. If w...

CLBTW - Greenhaven Road Capital Main Fund Q1 2024 Investor Letter

2024-04-28 07:20:00 ET Summary Greenhaven Road is a boutique hedge fund with the patience and confidence to step outside of the norm. Greenhaven Road Capital digs deep, searching in places rarely trafficked to locate the few hidden gems that will outperform a diversified portfolio of ...

CLBTW - Cellebrite to Report First-Quarter 2024 Financial Results on May 23, 2024

TYSONS CORNER, Va. and PETAH TIKVA, Israel, April 10, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its first-quarter 2024 financial results before market op...

CLBTW - Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd (Nasdaq: CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the appointment of David Gee as Chief Marketing Officer (CMO). Mr. Gee brings mor...

CLBTW - Cellebrite Files its 2023 Annual Report on Form 20-F

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended De...

Next 10